Skip to main content
Article thumbnail
Location of Repository

Predictors of orphan drug approval in the European Union

By Harald E. Heemstra, Remco L. de Vrueh, Sonja van Weely, Hans A. Büller and Hubert G. M. Leufkens
Topics: Pharmacoepidemiology and Prescription
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2668549
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2002). A
    2. (2006). A journey of hope: lessons learned from studies on rare diseases and orphan drugs.
    3. (2000). A proposal to improve the supply of orphan drugs.
    4. (2005). Adopting an orphan.
    5. (2006). Adopting orphan drugs-two dozen years of treating rare diseases.
    6. (2006). Are rare diseases still orphans or happily adopted? The challenges of developingand using orphan medicinal products.
    7. (2004). Background paper: orphan diseases. In: Kaplan W, Laing R (eds) Priority medicines for Europe and the world - a public health approach to innovation. World Health Organisation,
    8. (1997). Ceci A
    9. (2005). COMP report to the commission in relation to article 10 of regulation 141/2000 on orphan medicinal products.
    10. (2007). Drugs for rare diseases: mixed assessment in Europe
    11. (2006). Inventory of community and member states’ incentive measures to aid the research, marketing and development and availability of orphan medicinal products. Revision
    12. (1999). No 141/2000 of the European Parliament and of the
    13. (2006). Orphan drug development is progressing too slowly.
    14. (2005). Rare diseases: understanding this public health priority.
    15. (2006). Rare essentials: drugs for rare diseases as essential medicines.
    16. (2007). Register of designated orphan medicinal products. http://ec.europa.eu/enterprise/pharmaceuticals/ register/orphreg.htm.
    17. (2005). SME Office. http://www.emea.europa.eu/SME/ SMEbackground.htm.
    18. (2006). The impact of the Orphan Drug Act on drug discovery. Expert Opin Drug Discov 1:521–524
    19. (1983). The Orphan Drug Act,
    20. (2002). Two decades of orphan product development. Nat Rev Drug Discov 1:821–825

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.